AlloVir (Nasdaq:ALVR) - Hisse Senedi Fiyatı, Haberler ve Analizler

ALVR Stoklara Genel Bakış

ALVR temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Son 3 ayda dalgalı hisse senedi fiyatı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

+ 1 daha fazla risk

AlloVir, Inc. Rakipler

Cue Biopharma

NasdaqCM:CUE

US$64.6m

Spero Therapeutics

NasdaqGS:SPRO

US$63.2m

Cellectar Biosciences

NasdaqCM:CLRB

US$64.1m

BioAtla

NasdaqGM:BCAB

US$75.9m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti AlloVir
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.55
52 Haftanın En Yüksek Seviyesi	US$2.49
52 Haftanın En Düşük Seviyesi	US$0.52
Beta	0.74
11 Aylık Değişim	-31.52%
3 Aylık Değişim	-29.56%
1 Yıllık Değişim	-64.52%
33 Yıllık Değişim	-96.99%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-97.83%

Son Haberler & Güncellemeler

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Oct 29

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Jul 13

Recent updates

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04

AlloVir EPS misses by $0.28

Nov 10

Hissedar Getirileri

	ALVR	US Biotechs	US Pazar
7D	-3.4%	2.5%	2.2%
1Y	-64.5%	16.1%	31.6%

Getiri vs. Endüstri: ALVR geçen yıl % 16.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: ALVR geçen yıl % 31.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ALVR's price volatile compared to industry and market?
ALVR volatility
ALVR Average Weekly Movement	15.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ALVR hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ALVR 'nin haftalık oynaklığı ( 16% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2013	8	Diana Brainard	www.allovir.com

Klinik aşamada bir hücre tedavisi şirketi olan Allovir, Inc. yıkıcı viral ilişkili hastalıkları önlemek ve tedavi etmek için allojenik, kullanıma hazır çoklu virüse özgü T hücresi (VST) tedavilerinin araştırılması ve geliştirilmesiyle ilgilenmektedir. Şirketin öncü ürünü, BK virüsü, sitomegalovirüs, adenovirüs, Epstein-Barr virüsü, insan herpes virüsü 6 ve JC virüsünü tedavi etmek için allojenik, kullanıma hazır bir VST tedavisi olan posoleucel'dir. Klinik öncesi ve klinik geliştirme ürün adayları arasında solunum sinsityal virüsü, influenza, parainfluenza virüsü ve insan metapnömovirüsü için ALVR106; SARS-CoV-2 ve COVID-19 tedavisi için ALVR109; hepatit B tedavisi için ALVR107; ve ALVR108 bulunmaktadır.

AlloVir, Inc. Temel Bilgiler Özeti

AlloVir'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ALVR temel i̇stati̇sti̇kler
Piyasa değeri	US$62.92m
Kazançlar(TTM)	-US$100.20m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.6x

F/K Oranı

ALVR aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ALVR gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$100.20m
Kazançlar	-US$100.20m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.88
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

ALVR uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ALVR Stoklara Genel Bakış

Risk Analizi

AlloVir, Inc. Rakipler

NasdaqCM:CUE

US$64.6m

NasdaqGS:SPRO

US$63.2m

NasdaqCM:CLRB

US$64.1m

NasdaqGM:BCAB

US$75.9m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

New minor risk - Share price stability

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Recent updates

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

New minor risk - Share price stability

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

New major risk - Financial position

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Levi & Korsinsky, LLP Notifies Investors in Allovir, Inc. of a Class Action Securities Lawsuit

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Robbins LLP Announces Class Action File Against AlloVir, Inc

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Price target decreased by 71% to US$5.63

AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

New major risk - Share price stability

AlloVir, Inc. Presents Positive Final Results from A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of Bk Infection in Kidney Transplant Recipients At the American Transplant Congress

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target decreased by 7.6% to US$21.25

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Price target decreased by 13% to US$23.00

CEO & Director notifies of intention to sell stock

AlloVir, Inc. Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

AlloVir, Inc. Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

General Counsel & Secretary notifies of intention to sell stock

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir, Inc. Announces That Final Data from the Phase 2 Study of Posoleuce

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board notifies of intention to sell stock

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board recently sold US$2.9m worth of stock

Chief Commercial Officer recently sold US$129k worth of stock

Price target decreased to US$27.50

AlloVir GAAP EPS of $0.69 beats by $1.42

AlloVir stock surges on $126.6M securities offering

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 2000 Growth Index

AlloVir, Inc. Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

Chief Commercial Officer recently sold US$67k worth of stock

Price target decreased to US$32.00

FDA Grants Regenerative Medicine Advanced Therapy to Allovir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, Inc., Annual General Meeting, May 17, 2022

AlloVir Announces Appointment of Shawn Tomasello to its Board of Directors

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Chief Commercial Officer recently sold US$128k worth of stock

AlloVir: A Comparative Study Of Its Manufacturing Process

Price target decreased to US$38.75

Insider notifies of intention to sell stock

President recently sold US$56k worth of stock

AlloVir, Inc. Announces U.S. Food and Drug Administration Grant Lead Multi-Virus Specific T Cell (VST) Therapy, Posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Adenovirus (AdV) Infection

Price target decreased to US$42.75

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Chief Commercial Officer recently sold US$321k worth of stock